Transcode Therapeutics

Company snapshot

Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628. Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Transcode Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Transcode Therapeutics.

1. May 23, 2026 Clinical update

   TTX-MC138 — Phase 2

2. May 23, 2026 Clinical update

   TTX-MC138-NODAGA-Cu64 — Phase 1

View all clinical trial activity →

• What is Transcode Therapeutics?

  Transcenta Therapeutics is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker RNAZ. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entit

• Is Transcode Therapeutics publicly traded?

  Yes. Transcode Therapeutics is listed with ticker RNAZ on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Transcode Therapeutics develop or market?

  No drug profiles are currently linked to Transcode Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Transcode Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Transcode Therapeutics focus on?

  Transcode Therapeutics focuses on Advanced Solid Tumor based on our analysis of their pipeline programs and drug development activities.